Skip to main content
HeartSciences Inc. logo

HeartSciences Inc. — Investor Relations & Filings

Ticker · HSCS ISIN · US42254E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 235 across all filing types
Latest filing 2023-04-11 Capital/Financing Update
Country US United States of America
Listing US HSCS

About HeartSciences Inc.

https://heartsciences.com/

HeartSciences Inc. is a medical technology company that specializes in applying artificial intelligence (AI) and deep learning to electrocardiography (ECG). The company's core focus is on developing proprietary, device-agnostic AI-ECG algorithms to enhance the clinical utility of the standard ECG. By analyzing waveform data, its technology aims to enable earlier and more accurate detection of heart disease and other cardiac conditions that are often missed by traditional interpretation methods. A key application of its research involves creating algorithms to predict specific conditions, such as cardiomyopathy, from ECG signals.

Recent filings

Filing Released Lang Actions
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares by a selling shareholder. It includes detailed information about the offering, risk factors, use of proceeds, selling shareholder, and plan of distribution. The document is not a financial report, earnings release, or management discussion but rather a registration and offering document for securities. This type of filing corresponds to a capital raising or financing update, specifically a prospectus related to share resale and purchase agreements. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback.
2023-04-11 English
Regulatory Filings 2023
Regulatory Filings
2023-04-11 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It is a correspondence related to a securities registration process, specifically a request under Rule 461 of the Securities Act. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to a capital raising process but is not itself a capital/financing update or a registration statement filing. Given the nature of the document as a regulatory correspondence and request, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2023-04-06 English
Regulatory Filings 2023
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Due to the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but without meaningful content, it cannot be classified as a financial or corporate report.
2023-04-06 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the proposed sale of common stock by the company Heart Test Laboratories, Inc. The document includes a preliminary prospectus, details about the offering, risk factors, use of proceeds, and other information typical of a registration statement for an initial public offering or secondary offering. This type of filing is related to capital raising and financing activities, specifically the registration of securities for sale to the public. Therefore, it fits the category of Capital/Financing Update (CAP). The document is not an annual or quarterly report, audit report, earnings release, or any other category defined in the list. The length and content confirm it is a full registration statement, not just an announcement or a brief notice.
2023-03-29 English
424B3
Remuneration Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 23, 2023, for Heart Test Laboratories, Inc. It details the approval and grant of stock options to executive officers and directors, including terms of vesting and exercise price. The document includes references to the company's equity incentive plan and stock option agreements. The primary content is about compensatory arrangements for officers and directors, specifically stock option awards. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual report. The document is not a proxy solicitation or voting results announcement, but it relates to management compensation. According to the filing definitions, reports detailing compensation for top executives and directors fall under Remuneration Information (DEF 14A). Although this is a Form 8-K, the content is focused on executive and director compensation awards, which aligns with Remuneration Information. Therefore, the appropriate classification is DEF 14A with high confidence.
2023-03-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.